Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher Cousins

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Scientific Reports|October 2, 2020
Reproductive characteristics of American bullfrogs (Lithobates catesbeianus) in their invasive range of the Pacific Northwest, USAJenny Urbina, Evan M Bredeweg, Christopher Cousins, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 24, 2025
Xpert MTB/RIF® cycle threshold as a marker of TB disease severity; Implications for TB treatment stratificationDaniel J Grint, Jasvir Dhillon, Philip D Butcher, et al.
The New England Journal of Medicine|February 22, 2023
Treatment Strategy for Rifampin-Susceptible TuberculosisNicholas I Paton, Christopher Cousins, Celina Suresh, et al.
The Lancet. Infectious Diseases|May 25, 2025
Efficacy and safety of 8-week regimens for the treatment of rifampicin-susceptible pulmonary tuberculosis (TRUNCATE-TB): a prespecified exploratory analysis of a multi-arm, multi-stage, open-label, randomised controlled trialNicholas I Paton, Christopher Cousins, Intan P Sari, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Scientific Reports|October 2, 2020
Reproductive characteristics of American bullfrogs (Lithobates catesbeianus) in their invasive range of the Pacific Northwest, USAJenny Urbina, Evan M Bredeweg, Christopher Cousins, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 24, 2025
Xpert MTB/RIF® cycle threshold as a marker of TB disease severity; Implications for TB treatment stratificationDaniel J Grint, Jasvir Dhillon, Philip D Butcher, et al.
The New England Journal of Medicine|February 22, 2023
Treatment Strategy for Rifampin-Susceptible TuberculosisNicholas I Paton, Christopher Cousins, Celina Suresh, et al.
The Lancet. Infectious Diseases|May 25, 2025
Efficacy and safety of 8-week regimens for the treatment of rifampicin-susceptible pulmonary tuberculosis (TRUNCATE-TB): a prespecified exploratory analysis of a multi-arm, multi-stage, open-label, randomised controlled trialNicholas I Paton, Christopher Cousins, Intan P Sari, et al.
Pageof 1